A phase Ib study to investigate the safety and effect of BR-003

2024-516338-37-00 Protocol STX-102 Human pharmacology (Phase I) - First administration to humans Ended

Start 11 May 2023 · End 19 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol STX-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 12
Countries 1
Sites 1

Patients planned for open or percutaneous posterior spinal stabilisation with 4 or 6 pedicle screws with a diameter of 5 to 7.5 mm (inclusive), with or without concomitant posterolateral fusion, vertebral augmentation, intervertebral body fusion devices, osteotomies, and posterior decompression.

Key facts

Sponsor
SentryX B.V.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Analytical,Diagnostic,Therapeutic Techniques and Equipment [E]-Surgical Procedures, Operative [E04]
Trial duration
11 May 2023 → 19 Feb 2025
Decision date (initial)
2024-08-09
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516338-37-00
EudraCT number
2022-001069-11

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients planned for open or percutaneous posterior spinal stabilisation with 4 or 6 pedicle screws with a diameter of 5 to 7.5 mm (inclusive), with or without concomitant posterolateral fusion, vertebral augmentation, intervertebral body fusion devices, osteotomies, and posterior decompression.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

SentryX B.V.

Sponsor organisation
SentryX B.V.
Address
Yalelaan 54
City
Utrecht
Postcode
3584 CM
Country
Netherlands

Scientific contact point

Organisation
SentryX B.V.
Contact name
Jorrit-Jan Verlaan

Public contact point

Organisation
SentryX B.V.
Contact name
Suzanne Bruins

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 6 1
Rest of world
Switzerland
6

Investigational sites

Netherlands

1 site · Ended
Stichting Elisabeth-Tweesteden Ziekenhuis
Orthopedie, Hilvarenbeekseweg 60, 5022 GC, Tilburg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-05-11 2025-02-18 2023-05-11 2024-08-13

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-05 Netherlands Acceptable
2024-08-09
2024-08-09